Spectral Medical Inc.

TSX:EDT.TO

Medical - Diagnostics & Research

Healthcare
$1.04 -1.45%

-$0.02 today

Market cap
$306.00M
Beta
0.23
P/E (TTM)
-10.5
EPS (TTM)
-$0.13
52W Low $0.77High $1.84

Volume 0.02M

Average 0.06M

EDT.TO Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Spectral Medical Inc.TSX: EDT.TO

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development remains negative

Q1 FY2026 research & development was CA$0, compared with CA$1.59M a year earlier. Trailing-twelve-month research & development was CA$1.84M.

Context

  • Research & development amounted to 177.5% of revenue in FY2025, up 3.7 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly research & development holds near CA$0 or moves back toward the trailing-twelve-month quarterly average of CA$460.5K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$0— QoQ
Last fiscal yearDec 2025
CA$4.33M+9.1% YoY
LTMMar 2026
CA$1.84M-59.9% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year+9.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Research & Development history

CAD · from the income statement

Latest · FY2025
4.33M CAD
Year-over-year change
+9.1%

Research & Development vs competitors

How EDT.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -59.9% is the 6th highest of 7, against a peer median of -4.0%.
  • Research & development amounts to 66.7% of revenue for EDT.TO, versus a peer median of 1.0%.
EDT.TO Competitors
Research & Development for EDT.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EPRX.TOEupraxia Pharmaceuticals Inc.LTM Mar 2026$27.07M USD+139.8%+7.0%—
PRN.TOProfound Medical Corp.LTM Mar 2026$20.97M USD+17.5%+12.6%111.8%
KSI.TOKneat.com, Inc.LTM Mar 2026CA$13.33M CAD-25.6%-7.0%20.0%
ACB.TOAurora Cannabis Inc.LTM Mar 2026CA$4.85M CAD+31.9%-15.1%1.5%
EDT.TOSpectral Medical Inc.LTM Mar 2026CA$1.84M CAD-59.9%—66.7%
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 2026$205.18K USD-48.4%-58.4%0.4%
WEED.TOCanopy Growth CorporationLTM Mar 2026CA$0 CAD——0.0%
CPH.TOCipher Pharmaceuticals Inc.LTM Mar 2026$0 USD-100.0%-39.8%0.0%
Peer median (excluding EDT.TO) —-4.0%-11.0%1.0%

Competitors are the stored peer set for EDT.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2M1.67M1.6M2.29M2.44M
Cost of Revenue832K684K936K1.27M7.6M
Gross Profit1.16M983K662K1.02M(5.16M)
Gross Margin58.3%59.0%41.4%44.5%-211.1%
Research & Development004.68M3.97M4.33M
Selling, General & Admin7.01M8.64M11.29M11.62M11.73M
Operating Expenses7.86M9.43M12.08M13.02M6.53M
Depreciation & Amortization294K272K218K251K250K
EBITDA(6.38M)(7.18M)(13.96M)(11.97M)(11.44M)
EBITDA Margin-319.4%-430.7%-873.3%-523.5%-468.3%
Operating Income(6.66M)(8.45M)(11.42M)(12M)(11.69M)
Operating Margin-333.5%-506.7%-714.7%-524.8%-478.5%
Interest Income00005.39M
Interest Expense28K176K1.33M3.18M5.16M
Other Income / Expenses(40K)819K(4.09M)(3.4M)(36M)
Income Before Tax(6.96M)(7.63M)(15.51M)(15.4M)(47.69M)
Pre-Tax Margin-348.6%-457.6%-970.4%-673.4%-1952.9%
Income Tax Expense00000
Net Income(8.79M)(11.28M)(15.66M)(15.4M)(47.69M)
Net Margin-440.1%-676.7%-980.1%-673.8%-1953.0%
EPS (Basic)(0.03)(0.04)(0.06)(0.05)(0.17)
EPS (Diluted)(0.03)(0.04)(0.06)(0.05)(0.17)
Weighted Avg Shares252.46M269.84M278.56M281.08M287.21M
Weighted Avg Shares (Diluted)252.46M269.84M278.56M281.08M287.21M

Spectral Medical Inc.

TSX:EDT.TO

Intrinsic Alpha fair value

Locked

Current Price

$1.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.